New insider activity at Idexx Laboratories ( (IDXX) ) has taken place on February 11, 2025.
Director Anne Szostak has recently made a significant move by selling 3,000 shares of Idexx Laboratories stock. The transaction was valued at an impressive $1,397,820, highlighting the substantial worth of these shares.
Recent Updates on IDXX stock
Recent developments surrounding Idexx Laboratories have led to multiple analysts adjusting their price targets upwards. Piper Sandler raised its price target due to updated estimates and moving its estimate year to 2026, reflecting confidence in the company’s future performance. Additionally, BofA increased its target following a strong Q4 earnings report and promising FY25 guidance, although it maintains a neutral stance due to perceived limited upside without broader market improvement. Barclays also raised its target, citing a Q4 beat and healthy 2025 revenue guidance. The company reported a 6% revenue increase in Q4, driven by its Companion Animal Group and diagnostics recurring revenue, alongside a 13% rise in EPS. Idexx’s strategic initiatives, including product innovations like the inVue Dx Cellular Analyzer, and international growth further bolster its market position. Despite challenges such as a decline in US clinical visits and litigation expenses, Idexx projects continued growth with a revenue range of $4,055 million to $4,170 million for 2025 and plans significant share repurchases.
More about Idexx Laboratories
YTD Price Performance: 12.46%
Average Trading Volume: 652,236
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $37.65B